Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Inhibitor Combination Therapy in NSCLC After Neoadjuvant Immunotherapy
NCT06620822Phase 2Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Sep 2024
- Primary completion
- Sep 2026
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of IBI363, LM-108 and IBI310 in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Disease-Free Survival at 2 years. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
IBI363LM-108IBI310
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06620822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06620822.